Q4: Sales SEK 58m, +129% y-o-y, EBIT margin 29% '25e-'26e sales up 10-12% and EBIT adj.
Q4 is a reminder that Ascelia ticked some essential boxes during 2024, including completing a succes...
Redeye comments on Leqembi’s Q4 sales, which were a bit better than we expected, disclosed earlier t...
Redeye retains its positive view of Hexatronic following the Q4 report, showing a stable quarter in ...
Redeye updates its estimates following CTEK’s Q4 report, which was largely impacted by General Motor...
LapWall’s Q4 was slightly stronger than we expected in terms of profitability.
The company downgraded its 2024 guidance in December, dampening expectations for the Q4 numbers.
Redeye reinforces its positive view of Transtema following a strong Q4, where Sweden improved substa...
Analysguiden ser ljust på framtiden för Eastnine efter årets två förvärv i Polen.
Redeye returns to covering Sedana Medical and presents its preview for the company’s Q4 report, whic...
LapWall's fourth quarter performance was solid, despite net sales falling 13% y/y.
Redeye provides a research note on Faron Pharmaceuticals following the outcome of the company’s rece...
Better Collective has released preliminary results for Q4 which were stronger than expected, support...
Redeye continues to be positive to Bredband2 following a Q4 report in line with our estimates, posti...
Redeye comments on Göran Forsberg leaving as CEO with Damian Marron from the board taking the role ...
